Brixadi

Brixadi is a medication used in the treatment of opioid use disorder. It is a long-acting injectable formulation of buprenorphine, which is a partial opioid agonist. Brixadi is designed to provide sustained release of buprenorphine over a period of time, helping to reduce withdrawal symptoms and cravings in individuals with opioid dependence.

Mechanism of Action

Brixadi works by binding to the mu-opioid receptor in the brain, which helps to alleviate withdrawal symptoms and reduce cravings for opioids. As a partial agonist, buprenorphine activates the opioid receptors but to a lesser extent than full agonists like heroin or morphine. This property helps to lower the potential for misuse and dependence.

Administration

Brixadi is administered as a subcutaneous injection, typically in the abdominal region. The medication is available in different dosages, allowing healthcare providers to tailor the treatment to the individual needs of the patient. The frequency of administration can vary, but it is generally given on a weekly or monthly basis.

Indications

Brixadi is indicated for the treatment of moderate to severe opioid use disorder in patients who have been inducted on a stable dose of transmucosal buprenorphine. It is used as part of a comprehensive treatment plan that includes counseling and psychosocial support.

Side Effects

Common side effects of Brixadi include:

• Headache
• Nausea
• Vomiting
• Constipation
• Injection site reactions

Serious side effects may include respiratory depression, especially when used in combination with other central nervous system depressants.

Regulatory Status

Brixadi has been approved by various regulatory agencies for the treatment of opioid use disorder. It is classified as a Schedule III controlled substance under the Controlled Substances Act in the United States, indicating a moderate to low potential for physical and psychological dependence.

Related Pages

• Buprenorphine
• Opioid use disorder
• Opioid agonist
• Heroin
• Morphine
• Controlled Substances Act